Drug Profile
Research programme: cancer immunotherapy - Immunovative Therapies
Alternative Names: host-versus-tumour effect; MirrorEffect™Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Immunovative Therapies
- Class Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Cancer in Israel (IV, Infusion)
- 19 Jul 2013 Early research in Cancer in Israel (IV)